CrowMKRonnblomL. Type I interferons in host defence and inflammatory diseases. Lupus Sci Med2019; 6(1): e000336.
2.
BastardPRosenLBZhangQ, et al.Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science2020; 370(6515): eabd4585.
3.
MathianABreillatPDorghamK, et al.Lower disease activity but higher risk of severe COVID-19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α. Ann Rheum Dis2022; 81(12): 1695–1703.
4.
TummalaRAbreuGPinedaL, et al.Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med2021; 8(1): e000464.
5.
MorandEFFurieRTanakaY, et al.Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med2020; 382(3): 211–221.
6.
KalunianKCFurieRMorandEF, et al.A randomized, placebo-controlled phase III extension trial of the long-term safety and tolerability of anifrolumab in active systemic lupus erythematosus. Arthritis Rheumatol2022. https://onlinelibrary.wiley.com/doi/abs/10.1002/art.42392
7.
WardILBerminghamCAyoubkhaniD, et al.Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ2022; 378: e070695.
